Outlook Therapeutics is preparing for the U.S. launch of its FDA-approved drug LYTENAVA, focusing on retinal diseases. The company has recently appointed a new CFO to strengthen its financial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results